Catalyst Funds Management Pty LTD Viridian Therapeutics, Inc.\De Transaction History
Catalyst Funds Management Pty LTD
- $455 Billion
- Q3 2024
A detailed history of Catalyst Funds Management Pty LTD transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Catalyst Funds Management Pty LTD holds 1,900 shares of VRDN stock, worth $36,689. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,900Holding current value
$36,689% of portfolio
0.01%Shares
3 transactions
Others Institutions Holding VRDN
# of Institutions
178Shares Held
76.6MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$92.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$85.4 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$75 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$72.4 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$66.5 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $770M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...